81 FR 71747 - Office of The Director, Office of Science Policy, Office of Biotechnology Activities; Amended Notice of Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 81, Issue 201 (October 18, 2016)

Page Range		71747-71747
FR Document		2016-25072

Federal Register, Volume 81 Issue 201 (Tuesday, October 18, 2016)

[Federal Register Volume 81, Number 201 (Tuesday, October 18, 2016)]
[Notices]
[Page 71747]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2016-25072]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Office of The Director, Office of Science Policy, Office of 
Biotechnology Activities; Amended Notice of Meeting

    Notice is hereby given of a change in the meeting of the National 
Science Advisory Board for Biosecurity, November 04, 2016, 12:00 p.m. 
to November 04, 2016, 03:00 p.m., National Institutes of Health, 6705 
Rockledge Drive, Suite 750, Bethesda, MD 20892 which was published in 
the Federal Register on October 11, 2016, 81FR 196.
    The call-in number has changed to 1 (866) 939-3921. The meeting 
date, time and location remains the same. The meeting is open to the 
public.

    Dated: October 12, 2016.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2016-25072 Filed 10-17-16; 8:45 am]
 BILLING CODE 4140-01-P

Federal Register / Vol. 81, No. 201 / Tuesday, October 18, 2016 / Notices 71747

the Department of Health and Human limitations imposed by the review and confidential trade secrets or commercial
Services: funding cycle. property such as patentable material,
(Catalogue of Federal Domestic Assistance and personal information concerning
Last name First name Program Nos. 93.375, Minority Biomedical individuals associated with the grant
Research Support; 93.821, Cell Biology and applications, the disclosure of which
Avula ......................... Deepa Biophysics Research; 93.859, Pharmacology,
Physiology, and Biological Chemistry would constitute a clearly unwarranted
Corierre ..................... Michael
Del Vecchio ............... Paolo Research; 93.862, Genetics and invasion of personal privacy.
Enomoto .................... Kana Developmental Biology Research; 93.88, Name of Committee: National Institute on
Etzinger ..................... Michael Minority Access to Research Careers; 93.96, Drug Abuse Special Emphasis Panel;
Feit ............................ Monica Special Minority Initiatives; 93.859, Growing Great Ideas: Research Education
Goldstein ................... Gregory Biomedical Research and Research Training, Course in Product Development and
Harding ...................... Frances National Institutes of Health, HHS) Entrepreneurship for Life Science
Hendriksson .............. Marla Dated: October 12, 2016. Researchers (R25).
Johnson ..................... Kimberly Date: October 24, 2016.
Kade .......................... Daryl Melanie J. Gray,
Time: 1:00 p.m. to 5:00 p.m.
Lopez ........................ Elizabeth Program Analyst, Office of Federal Advisory Agenda: To review and evaluate grant
Power ........................ Kathryn Committee Policy. applications.
Wheeles .................... Timothy (NIH) [FR Doc. 2016–25071 Filed 10–17–16; 8:45 am] Place: National Institutes of Health,
BILLING CODE 4140–01–P Neuroscience Center, 6001 Executive
Michael Etzinger, Boulevard, Rockville, MD 20852, (Telephone
Conference Call).
Executive Officer and Director, Office of Contact Person: Gerald L. McLaughlin,
Management, Technology and Operations. DEPARTMENT OF HEALTH AND
HUMAN SERVICES Ph.D., Scientific Review Officer, Office of
Carlos Castillo, Extramural Policy and Review, National
SAMHSA Committee Management Officer, National Institutes of Health Institute on Drug Abuse, NIH, DHHS, 6001
Office of Policy, Planning and Innovation. Executive Blvd., Room 4238, MSC 9550,
[FR Doc. 2016–25099 Filed 10–17–16; 8:45 am] Office of The Director, Office of Bethesda, MD 20892–9550, 301–827–5819,
gm145a@nih.gov.
BILLING CODE 4151–17–P Science Policy, Office of
Biotechnology Activities; Amended This notice is being published less than 15
days prior to the meeting due to the timing
Notice of Meeting
limitations imposed by the review and
DEPARTMENT OF HEALTH AND funding cycle.
HUMAN SERVICES Notice is hereby given of a change in
the meeting of the National Science Name of Committee: National Institute on
National Institutes of Health Advisory Board for Biosecurity, Drug Abuse Special Emphasis Panel;
November 04, 2016, 12:00 p.m. to Exploratory Studies of Smoking Cessation
National Institute of General Medical November 04, 2016, 03:00 p.m., Interventions for People with Schizophrenia.
Date: November 2, 2016.
Sciences; Notice of Closed Meeting National Institutes of Health, 6705 Time: 9:00 a.m. to 12:00 p.m.
Rockledge Drive, Suite 750, Bethesda, Agenda: To review and evaluate grant
Pursuant to section 10(d) of the MD 20892 which was published in the
Federal Advisory Committee Act, as applications.
Federal Register on October 11, 2016, Place: National Institutes of Health,
amended (5 U.S.C. App.), notice is 81FR 196. Neuroscience Center, 6001 Executive
hereby given of the following meeting. The call-in number has changed to 1 Boulevard, Rockville, MD 20852, (Telephone
The meeting will be closed to the (866) 939–3921. The meeting date, time Conference Call).
public in accordance with the and location remains the same. The Contact Person: Nadine Rogers, Ph.D.,
provisions set forth in sections meeting is open to the public. Scientific Review Officer, Office of
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Extramural Policy and Review, National
as amended. The grant applications and Dated: October 12, 2016. Institute on Drug Abuse, NIH, DHHS, 6001
the discussions could disclose David Clary, Executive Blvd., Room 4229, MSC 9550,
confidential trade secrets or commercial Program Analyst, Office of Federal Advisory Bethesda, MD 20892–9550, 301–827–5840,
property such as patentable material, Committee Policy. rogersn2@nida.nih.gov.
and personal information concerning [FR Doc. 2016–25072 Filed 10–17–16; 8:45 am] Name of Committee: National Institute on
individuals associated with the grant BILLING CODE 4140–01–P
Drug Abuse Special Emphasis Panel; NIDA
Medications Development.
applications, the disclosure of which
Date: November 4, 2016.
would constitute a clearly unwarranted Time: 8:30 a.m. to 5:00 p.m.
invasion of personal privacy. DEPARTMENT OF HEALTH AND
Agenda: To review and evaluate
HUMAN SERVICES cooperative agreement applications.
Name of Committee: National Institute of
General Medical Sciences Special Emphasis Place: Hilton Garden Inn Bethesda, 7301
National Institutes of Health Waverly Street, Bethesda, MD 20814.
Panel; Review of Mira Applications.
Date: November 9–10, 2016. Contact Person: Jose F. Ruiz, Ph.D.,
National Institute on Drug Abuse; Scientific Review Officer, Office of
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
Notice of Closed Meetings Extramural Policy and Review, National
applications. Pursuant to section 10(d) of the Institute on Drug Abuse, NIH, Room 4228,
Place: Washington Plaza Hotel, Ten Federal Advisory Committee Act, as MSC 9550, 6001 Executive Blvd., Bethesda,
Thomas Circle, Washington, DC 20005. MD 20892–9550, 301–827–5842, ruizjf@
Contact Person: Lisa A. Dunbar, Scientific
amended (5 U.S.C. App), notice is nida.nih.gov.
Lhorne on DSK30JT082PROD with NOTICES

Review Officer, Office of Scientific Review, hereby given of the following meetings.
Name of Committee: National Institute on
National Institute of General Medical The meetings will be closed to the
Drug Abuse Special Emphasis Panel; Multi-
Sciences, National Institutes of Health, 45 public in accordance with the site Clinical Trials.
Center Drive, Room 3AN12, Bethesda, MD provisions set forth in sections Date: November 9, 2016.
20892, 301–594–2849, dunbarl@mail.nih.gov. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Time: 3:00 p.m. to 5:00 p.m.
This notice is being published less than 15 as amended. The grant applications and Agenda: To review and evaluate grant
days prior to the meeting due to the timing the discussions could disclose applications.

VerDate Sep<11>2014 13:19 Oct 17, 2016 Jkt 241001 PO 00000 Frm 00059 Fmt 4703 Sfmt 4703 E:\FR\FM\18OCN1.SGM 18OCN1

Document Created: 2016-10-17 23:52:36
Document Modified: 2016-10-17 23:52:36

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
FR Citation		81 FR 71747

81 FR 71747 - Office of The Director, Office of Science Policy, Office of Biotechnology Activities; Amended Notice of Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 81, Issue 201 (October 18, 2016)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health